Evidence map›Paper›PMID 41120399›Full record

ArticleScientific reports2025

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes.

Fumiko Murao, Ryoji Yanai, Sentaro Kusuhara, Yuki Abe, Masahiko Shimura, Hiromi Ohara, Hiroto Terasaki, Masahiko Sugimoto, Hisashi Matsubara, Yoshio Hirano and 6 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fumiko MuraoDepartment of Ophthalmology, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. murao.fumiko.2@tokushima-u.ac.jp.
Ryoji YanaiDepartment of Ophthalmology, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.
Sentaro KusuharaDepartment of Ophthalmology, Kobe University, Kobe, Japan.
Yuki AbeDepartment of Ophthalmology, Fukui University, Yoshida, Japan.
Masahiko ShimuraDepartment of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Hiromi OharaDepartment of Ophthalmology, Hiroshima University, Hiroshima, Japan.
Hiroto TerasakiDepartment of Ophthalmology, Kagoshima University, Kagoshima, Japan.
Masahiko SugimotoDepartment of Ophthalmology, Yamagata University, Yamagata, Japan.
Hisashi MatsubaraDepartment of Ophthalmology, Mie University, Tsu, Japan.
Yoshio HiranoDepartment of Ophthalmology, Nagoya City University, Nagoya, Japan.
Takamasa KinoshitaDepartment of Ophthalmology, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
Hiroki TsujinakaDepartment of Ophthalmology, Nara Medical University, Kashihara, Japan.
Kyosuke SekiDepartment of Ophthalmology, National Defense Medical College, Tokorozawa, Japan.
Takeshi IwaseDepartment of Ophthalmology, Akita University, Akita, Japan.
Yoshinori MitamuraDepartment of Ophthalmology, Tokushima University, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.
J-CREST

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the real-world efficacy of intravitreal faricimab for diabetic macular edema (DME) and its relationship with visual and retinal anatomical changes using optical coherence tomography. We retrospectively assessed 174 patients (214 eyes) with DME from 13 Japan Clinical REtina Study Group (J-CREST) sites who received ≥ 1 faricimab injection and were followed ≥ 6 months, and compared treatment-naïve (with no prior anti-VEGF treatment) and previously treated groups. Both groups showed significant improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST BCVA gain was greater in the treatment-naïve group (p = 0.0109), whereas CST reduction showed little difference (p = 0.31). Resolution of cystoid macular oedema, diffuse retinal thickening, and subretinal fluid (SRF) was observed in both groups. Resolution of inner nuclear layer (INL) oedema and SRF significantly correlated with ≥ 0.2 log MAR BCVA improvement in the treatment-naïve group (p = 0.043 and p = 0.022, respectively). Mean number of injections was comparable between groups. One case of anterior chamber inflammation occurred; however, no serious systemic events were observed. In conclusion, faricimab significantly improved visual and anatomical outcomes in DME, especially in treatment-naïve eyes. Early resolution of INL oedema and SRF may serve as a potential biomarker for visual prognosis.

Indexed as

Angiogenesis InhibitorsDiabetic RetinopathyMacular EdemaAgedAntibodies, BispecificBiomarkersFemaleHumansIntravitreal InjectionsMaleMiddle AgedRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVisual AcuityAngiogenesis InhibitorsAntibodies, BispecificBiomarkersfaricimabAnti-VEGF therapyDiabetic macular edemaFaricimabOptical coherence tomographyVisual acuity

Identifiers

PMID41120399
PMCPMC12540870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.